Clinical Trials Logo

Clinical Trial Summary

The investigators will examine how treatment with sertraline for 12 weeks impacts frontal-striatal-thalamic circuitry (FSTC) in this OCD sample.


Clinical Trial Description

To examine FSTC using advanced multi-modal imaging techniques, including resting-state functional magnetic resonance imaging (R-fMRI) and high angular resolution diffusion imaging (HARDI), in 25 medication-free adolescents youths with OCD (ages 8-17) in comparison with 25 matched healthy controls. Hypotheses: (A) Based on the pilot data, adolescents youths with OCD will show lower functional connectivity in FSTC at baseline when compared with controls, and , lower functional connectivity in FSTC will correlate with greater severity on CY-BOCS. (B) Adolescents Youths with OCD will also show abnormalities in structural connectivity in FSTC at baseline when compared with controls, and structural and functional connectivity will be related. (C) The investigators will explore relations between OCD dimensions and functional connectivity measures, and predict that the repeating/ordering dimension will correlate with orbitofrontal cortex (OFC) connections, hoarding will correlate with rostral anterior cingulate cortex (ACC) connections, and forbidden thoughts will correlate with caudal ACC connections. To investigate how sertraline impacts functional connectivity in FSTC in adolescents with OCD. Hypothesis: After 12 weeks of sertraline treatment, functional connectivity measures within FSTC for the OCD group will (on average) increase compared to baseline and will no longer be significantly different when compared with controls. Non-responders may show a different pattern (i.e. failure to show these changes). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02797808
Study type Interventional
Source University of Minnesota
Contact
Status Completed
Phase Phase 1/Phase 2
Start date August 2013
Completion date January 31, 2017

See also
  Status Clinical Trial Phase
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00215137 - Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder Phase 2
Recruiting NCT06050369 - Objective Characterizatoion of Repetitive Behaviors N/A
Recruiting NCT06347978 - Personalized DBS for OCD Guided by Stereoencephalography Mapping N/A
Withdrawn NCT03926546 - Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT05712057 - Neurostimulation Versus Therapy for Problems With Emotions N/A
Not yet recruiting NCT03313622 - Locating Biomarkers in OCD Through Behavioral Tasks
Withdrawn NCT03842345 - DELPhI Evaluation of Psychiatric Conditions
Completed NCT02866422 - Development of an Instrument That Monitors Behaviors Associated With OCD N/A
Completed NCT01833442 - Randomized Controlled Meditation Trial for Treating OCD N/A
Recruiting NCT04904952 - Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients N/A
Completed NCT05981690 - Therapist Guided, Parent-led, Cognitive Behavioural Therapy (CBT) for Preadolescent Children With Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT02500888 - Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder N/A
Recruiting NCT06244121 - Effect of Pyridoxine as Add-on Therapy in OCD Patients N/A
Recruiting NCT05580614 - Paired tVNS With ERP in OCD N/A
Active, not recruiting NCT03511534 - Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder N/A
Recruiting NCT05624528 - A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder Phase 2
Recruiting NCT05881356 - Discovering Factors in the Clinical Study Journey of Patients With OCD
Recruiting NCT05359562 - How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD N/A
Recruiting NCT03459456 - Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)